Levodropropizine: Uses, Dosage, Side Effects and More

Generic Medicine Info Patient Medicine Information

This information is not country-specific. Please refer to the Hong Kong prescribing information.

Generic Medicine Info

Indications and Dosage

Oral
Cough

Adult: For symptomatic relief: As conventional tab or oral syrup: 60 mg up to tid given at intervals of at least 6 hours. As controlled-release tab: 90 mg bid.
Child: For symptomatic relief: 2-12 years As oral syrup: 1 mg/kg tid given at intervals of at least 6 hours; >12 years As conventional tab or oral syrup: Same as adult dose.

What are the brands available for Levodropropizine in Hong Kong?

Hepatic Impairment

Severe: Contraindicated.

Administration

Levodropropizine IR formulation: Should be taken on an empty stomach.

Contraindications

Excessive mucus discharge or limited mucociliary function (e.g. Kartagener syndrome, bronchial cilia dyskinesia). Severe hepatic impairment. Pregnancy and lactation.

Special Precautions

Patient with severe heart failure. Severe renal impairment. Children.

Adverse Reactions

Significant: Rarely, drowsiness or altered consciousness.
Cardiac disorders: Palpitations.
Gastrointestinal disorders: Nausea, vomiting, diarrhoea, abdominal pain, heartburn.
General disorders and administration site conditions: Asthenia, fatigue.
Nervous system disorders: Somnolence, dizziness, headache.

Patient Counseling Information

This drug may cause drowsiness or dizziness, if affected, do not drive or operate machinery.

Drug Interactions

Additive sedation with sedatives.

Food Interaction

Additive sedation with alcohol.

Action

Description:
Mechanism of Action: Levodropropizine, the S-isomer of dropropizine, is a peripherally acting, non-opioid antitussive agent. It suppresses the cough reflex by inhibiting sensory C-fibre activation, reducing the release of neuropeptides and decreasing the excitability of tracheobronchial receptors.
Pharmacokinetics:
Absorption: Rapidly absorbed from the gastrointestinal tract. Bioavailability: >75%. Time to peak plasma concentration: Approx 0.75 hours (conventional form); approx 1 hour (controlled-release tab).
Distribution: Plasma protein binding: 11-14%.
Excretion: Via urine (35% as unchanged drug and metabolites). Elimination half-life: 2.3 ± 0.5 hours (conventional form); approx 3 ± 0.9 hours (controlled-release tab).

Chemical Structure

Storage

Store below 30°C. Protect from light.

MIMS Class

Cough & Cold Preparations

ATC Classification

R05DB27 - levodropropizine ; Belongs to the class of other cough suppressants.

References

Brayfield A, Cadart C (eds). Dropropizine. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 03/02/2025.

Inal Syrup (MacroPhar Co., Ltd). MIMS Thailand. http://www.mims.com/thailand. Accessed 03/02/2025.

Levare 60 mg Tablet (UNILAB, Inc.). MIMS Philippines. http://www.mims.com/philippines. Accessed 03/02/2025.

Levodropropizine. UpToDate Lexidrug, Lexi-Drugs Multinational Online. Waltham, MA. UpToDate, Inc. https://online.lexi.com. Accessed 03/02/2025.

LevoGen 30 mg/5 mL Syrup (Lloyd Laboratories Inc). MIMS Philippines. http://www.mims.com/philippines. Accessed 03/02/2025.

Levopront 30 mg/5 mL Syrup (Dompe International). MIMS Philippines. http://www.mims.com/philippines. Accessed 03/02/2025.

Levotics CR 90 mg Controlled-release Tablet (Korea United Pharma Inc). MIMS Philippines. http://www.mims.com/philippines. Accessed 03/02/2025.

Disclaimer: This information is independently developed by MIMS based on Levodropropizine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2025 MIMS. All rights reserved. Powered by MIMS.com